IOVA FY2025 SEC EDGAR DEF 14A #100 of 168 in industry

Iovance Biotherapeutics, Inc. CEO pay ratio

The CEO earned $4.8M in FY2025 against median worker pay of $153,409 · Chemicals & Pharmaceuticals.

Chemicals & Pharmaceuticals peers All rankings
State
DE
Filing date
2026-04-28
Industry
Chemicals & Pharmaceuticals
Industry rank
#100/168

Data updated August 2026

Subscribe to Iovance Biotherapeutics, Inc. CEO pay filing updates (RSS)

CEO-to-worker pay ratio
31:1
Below Average (Scale: 0–1000:1)
CEO pay
$4.8M
Median worker
$153,409

Answer first

Iovance Biotherapeutics, Inc.'s FY2025 CEO total of $4.8M ranks #953 of 1,423 complete filings; its 31:1 pay ratio ranks #1127. Dollar rank is not ratio rank.

According to the same FY2025 complete-filing cohort used on the rankings boards (CEO total, median worker, and ratio all present). Median worker pay is $153,409. Industry placement uses the FY2025 SIC-28 peer cohort (# 100 of 168, 41st percentile - below the industry median pay ratio). Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.

Dollar rank
#953
$4.8M of 1,423 FY2025
Ratio rank
#1127
31:1 of 1,423
Industry pct
41st
below the industry median pay ratio

How Iovance Biotherapeutics, Inc. ranks nationally

Iovance Biotherapeutics, Inc. CEO pay vs. every FY2025 complete filing

Total CEO compensation, the full national distribution, this company marked

$4,755,679 33rd percentile higher than 33% of 1,423 companies

$0–$2,500,000: 304 companies (21%). Below this entry. $2,500,000–$5,000,000: 182 companies (13%). This entry sits in this band. $5,000,000–$7,500,000: 208 companies (15%). Above this entry. $7,500,000–$10,000,000: 192 companies (13%). Above this entry. $10,000,000–$12,500,000: 139 companies (10%). Above this entry. $12,500,000–$15,000,000: 91 companies (6%). Above this entry. $15,000,000–$17,500,000: 88 companies (6%). Above this entry. $17,500,000–$20,000,000: 54 companies (4%). Above this entry. $20,000,000–$22,500,000: 24 companies (2%). Above this entry. $22,500,000–$25,000,000: 34 companies (2%). Above this entry. $25,000,000–$27,500,000: 24 companies (2%). Above this entry. $27,500,000–$30,000,000: 16 companies (1%). Above this entry. $30,000,000–$32,500,000: 10 companies (1%). Above this entry. $32,500,000–$35,000,000: 7 companies (0%). Above this entry. $35,000,000–$37,500,000: 9 companies (1%). Above this entry. $37,500,000–$40,000,000: 6 companies (0%). Above this entry. $40,000,000–$42,500,000: 1 companies (0%). Above this entry. $42,500,000–$45,000,000: 1 companies (0%). Above this entry. $45,000,000–$47,500,000: 6 companies (0%). Above this entry. $47,500,000–$50,000,000: 27 companies (2%). Above this entry. This company $0 $50M+ every complete-filing company, bucketed by value

Each bar is a $2500K-wide band; taller bars hold more companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source SEC DEF 14A Section 953(b) disclosures, PlainCEOPay extract · FY2025

Iovance Biotherapeutics, Inc. vs. Chemicals & Pharmaceuticals peers

CEO total pay ($4.8M) against pay ratio (31:1) for Iovance Biotherapeutics, Inc. (marked) and its 5 closest same-industry peers, against the Chemicals & Pharmaceuticals industry median on both axes.

Pay + gap both highContained pay, wide gapHigh pay, contained gapBelow peer norms on both3149280.95861815.4857435011286884.513999419.129.4:132.7:136:139.3:142.6:1CEO total payPay ratio (CEO : median worker)Iovance Biotherapeutics, Inc., CEO total pay: 4755679 · Pay ratio (CEO : median worker): 31:1Iovance Biotherapeutics, Inc.Green Plains Inc., CEO total pay: 3642469 · Pay ratio (CEO : median worker): 31:1Green Plains Inc.Protagonist Therapeutics, Inc, CEO total pay: 12852660 · Pay ratio (CEO : median worker): 30:1Protagonist Therapeutics, IncAlkermes plc., CEO total pay: 8002710 · Pay ratio (CEO : median worker): 30:1Alkermes plc.Janux Therapeutics, Inc., CEO total pay: 13506231 · Pay ratio (CEO : median worker): 30:1Janux Therapeutics, Inc.Recursion Pharmaceuticals, Inc., CEO total pay: 9503538 · Pay ratio (CEO : median worker): 33:1Recursion Pharmaceuticals, Inc.
Iovance Biotherapeutics, Inc. vs. Chemicals & Pharmaceuticals peers, plotted against the industry's $7.9M median CEO total and 42:1 median pay ratio.

Ratio bands among Chemicals & Pharmaceuticals peers

Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.

CEO Compensation Breakdown, FY2025

A component-level pay breakdown is not reported in Iovance Biotherapeutics, Inc.'s structured SEC pay-ratio disclosure. See our methodology →

Filing-year trail · Iovance Biotherapeutics, Inc.

Complete DEF 14A pay-ratio filings for this CIK across FY2021–2025. Year-over-year deltas compare adjacent filing years only; incomplete dollar rows are omitted (same completeness gate as the hero figures).

Latest ratio
31:1
FY2025
vs prior FY
+23:1
from FY2024 8:1
CEO $ YoY
+138%
$4.8M latest
Filings shown
5
FY2021–2025
Iovance Biotherapeutics, Inc. CEO total compensation, median worker pay, and pay ratio by fiscal year from SEC EDGAR DEF 14A.
FY CEO pay Δ pay Median worker Pay ratio Δ ratio
2021 $747K - $373,379 2:1 -
2022 $1.8M +147% $230,819 8:1 +6:1
2023 $199K -89% $199,048 1:1 -7:1
2024 $2.0M +905% $250,175 8:1 +7:1
2025 $4.8M +138% $153,409 31:1 +23:1

Source: SEC EDGAR DEF 14A pay-ratio disclosures for CIK 1425205, FY2021–2025. Adjacent-year deltas only.

Industry Comparison - Chemicals & Pharmaceuticals

This Company's Ratio
31:1
Industry Median Ratio
42:1
Industry Median CEO Pay
$7.9M
This CEO's Pay
$4.8M
Companies in Industry
168
vs. Industry Median
Below
#100 of 168 by pay ratio in this industry View all companies in Chemicals & Pharmaceuticals →

Iovance Biotherapeutics, Inc.: MODEST · MID$ pay ratio

Iovance Biotherapeutics, Inc.'s 31:1 ratio ranks #1127 of 1,423 FY2025 complete filings (lower third by ratio). the CEO earned 31× the median employee ($153,409) in FY2025.

Median employee $153,409 (ELITE-MED); MODEST · MID$ stamps put about 31 median-wage years per CEO year.

CEO Total Pay

$4.8M

FY2025 Summary Compensation, below median

Pay Ratio

31:1

Below typical

Iovance Biotherapeutics, Inc. in the lower-ratio third

Iovance Biotherapeutics, Inc.'s 31:1 ratio ranks #1127 of 1,423 FY2025 complete filings (lower third by ratio). The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; Iovance Biotherapeutics, Inc.'s $4.8M CEO total is at or below the $7.9M industry median CEO pay.

Dollar rank #953 and ratio rank #1127 split - treat 31:1 as a disclosure, not a fairness score. Open Chemicals & Pharmaceuticals peers.

Key Data, FY2025

Total Compensation
$4.8M
Median Employee Pay
$153,409
Pay Ratio
31:1
Filing Date
2026-04-28

Company Info

Ticker
IOVA
CIK
1425205
Industry
Chemicals & Pharmaceuticals
SIC Code
2836
State
DE
View SEC filings →
SEC EDGAR DEF 14A for CIK 1425205, FY2025. Informational only, not investment advice. Verify on EDGAR.

Read our methodology - how this data is sourced, computed, and verified. Iovance Biotherapeutics, Inc.'s 31:1 ratio ranks #1127 of 1,423 FY2025 complete filings (lower third by ratio).

Read with Iovance Biotherapeutics, Inc.

ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps MODEST · MID$ · ELITE-MED.

Gibraltar Industries, Inc. · MID$

ABS(ceo_total_comp) peer at $4.8M (Δ $2K lighter vs Iovance Biotherapeutics, Inc.); MODEST · HIGH-MED vs this page's MODEST · MID$ · ELITE-MED.
Community Health Systems Inc · MID$

ABS(ceo_total_comp) peer at $4.8M (Δ $17K heavier vs Iovance Biotherapeutics, Inc.); MODEST · HIGH-MED vs this page's MODEST · MID$ · ELITE-MED.
Bentley Systems Inc · MID$

ABS(ceo_total_comp) peer at $4.8M (Δ $25K heavier vs Iovance Biotherapeutics, Inc.); MODEST · HIGH-MED vs this page's MODEST · MID$ · ELITE-MED.
Black Stone Minerals, L.P. · MID$

ABS(ceo_total_comp) peer at $4.8M (Δ $32K heavier vs Iovance Biotherapeutics, Inc.); MODEST · ELITE-MED vs this page's MODEST · MID$ · ELITE-MED.
Green Plains Inc. (SIC 28 pole)

Green Plains Inc. stamps MODEST · MID$ nearest in-SIC by ABS(pay_ratio) to Iovance Biotherapeutics, Inc.'s MODEST filing.
National dual ranks · #953/#1127

Iovance Biotherapeutics, Inc.'s FY2025 package sits #953 by CEO dollars and #1127 by ratio under MID$ · MODEST.
Ratio primer · MODEST

Iovance Biotherapeutics, Inc.'s MODEST stamp sits in the lower Item 402(u) band - start with how the ratio is disclosed before comparing peers.
Data sourced from SEC EDGAR DEF 14A for Iovance Biotherapeutics, Inc. (CIK 1425205), FY2025. See our methodology. Aggregated by PlainCEOPay as of August 2026.

Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.